What is CJC-1295? In the simplest research terms: CJC-1295 is a synthetic analogue of growth hormone–releasing hormone (GHRH) — a 29-amino-acid peptide engineered with a modification that keeps it active in the body for days instead of minutes. It was developed to study sustained growth-hormone-axis activity, and it is one of the few research peptides with published human trial data. This explainer answers what is CJC-1295 from the ground up: its structure, the DAC modification that defines it, the variants researchers encounter in the literature, and the state of the research landscape. Everything is in research framing — no usage guidance, no human claims, no medical advice.
Research-use-only disclaimer: CJC-1295 is a research compound, not an approved medicine. This article explains what CJC-1295 is as a research subject. It contains no dosage information, no usage instructions, and no medical advice. All products on this site are sold strictly for laboratory research use.
What Is CJC-1295? The Short Answer
The short answer to what is CJC-1295: it is a laboratory-made copy of the body’s own growth hormone–releasing hormone, altered in two ways. First, four of the 29 amino acids are substituted relative to natural GHRH(1-29) — changes that improve stability and activity. Second, a lysine residue carries the Drug Affinity Complex (DAC), a chemical handle that binds to albumin in the bloodstream and stretches the peptide’s active life from minutes to days. The result is a long-acting GHRH analogue — a research tool for studying what sustained GHRH-receptor activation does. For the published findings from that research, see our companion roundup of CJC-1295 benefits in the literature.
Q: Is CJC-1295 a hormone?
A: It is a synthetic analogue of a hormone — modeled on GHRH, which the hypothalamus uses to signal the pituitary to release growth hormone. CJC-1295 itself is a laboratory-engineered peptide, not a naturally occurring hormone, and it exists only as a research compound.
Q: What does the “DAC” in CJC-1295 with DAC mean?
A: DAC stands for Drug Affinity Complex — a modification attached to the peptide that binds circulating albumin. Because albumin lingers in the bloodstream, the bound peptide is protected from rapid clearance, extending activity from the minutes of natural GHRH to days. The DAC is the defining engineering feature of the compound.
Q: What is CJC-1295 without DAC (sometimes called “no DAC” or Mod GRF)?
A: The literature and research-supply world distinguish CJC-1295 with DAC from the same GHRH-analogue sequence without the DAC modification — often labeled Mod GRF(1-29). The no-DAC version lacks the albumin-binding handle and therefore has a much shorter activity window, closer to natural GHRH. They are different research materials with different pharmacokinetic profiles, and the published human trial data attaches to the DAC version.
The Structure, Piece by Piece
For researchers who want the full answer to what is CJC-1295, the structure breaks down into three functional parts:
| Structural element | What it is | What it does |
|---|---|---|
| GHRH(1-29) backbone | The first 29 amino acids of growth hormone–releasing hormone | Binds the GHRH receptor on pituitary cells, triggering growth hormone release |
| Four amino-acid substitutions | Modified residues at key positions | Improve stability and receptor activity relative to the natural sequence |
| DAC (Drug Affinity Complex) | Albumin-binding chemical handle on a lysine residue | Extends circulation time from minutes to days by hitching to serum albumin |
Each element answers a different design question: the backbone provides the biological signal, the substitutions protect it, and the DAC keeps it around. That three-part logic is the whole engineering story of what CJC-1295 is — a natural signal, hardened and extended for research use.
How CJC-1295 Fits the Growth Hormone Axis
Understanding what CJC-1295 is requires the axis it acts on. The growth hormone axis runs hypothalamus → pituitary → liver and tissues: the hypothalamus releases GHRH, the pituitary responds by releasing growth hormone in pulses, and GH drives IGF-1 production and downstream metabolic effects. CJC-1295 enters this axis at the top — it mimics the hypothalamic signal. Published research reports that it amplifies the body’s own pulsatile GH release rather than replacing it with a constant signal, a distinction the literature treats as mechanistically important. Background on the axis is available at Wikipedia’s GHRH article and Wikipedia’s growth hormone article.
The Research Timeline
The what is CJC-1295 story is also a development history. A condensed timeline:
- Early 2000s: ConjuChem develops the DAC platform — the idea of extending peptide half-life via albumin binding — and applies it to a GHRH analogue. CJC-1295 is the resulting compound.
- Mid-2000s: Published clinical trials in healthy volunteers test single and repeated administration, measuring GH secretion, IGF-1 levels, and pharmacokinetics. The CJC-1295 human-trial literature — the findings summarized in our CJC-1295 benefits roundup — comes from this period.
- Late 2000s–2010s: Development as a therapeutic does not advance to an approved medicine. The compound transitions into the research-compound ecosystem: studied in laboratory settings and supplied for research use, with the trial literature remaining the primary evidence base.
- Present: CJC-1295 persists as a reference long-acting GHRH analogue in the research literature — cited in reviews of GH-axis pharmacology and compared against newer GHRH analogues and secretagogues in ongoing research.
What Is CJC-1295 Compared To? Related Research Compounds
Researchers asking what is CJC-1295 often encounter it alongside neighboring compounds. A brief map prevents confusion:
- Natural GHRH (somatocrinin): the 44-amino-acid hypothalamic hormone. CJC-1295 is modeled on its active 1–29 fragment, not the full hormone.
- Sermorelin: another GHRH(1-29) analogue — studied as a diagnostic and formerly approved medicine — but without the DAC modification, so with a short activity window. A different branch of the same family tree.
- GHRPs and secretagogues (e.g., ipamorelin, GHRP-6): these act on the ghrelin receptor, a different receptor on the same pituitary cells. Same downstream hormone, different upstream signal — a distinct research track from GHRH analogues.
- Mod GRF(1-29): the CJC-1295 sequence without DAC — same substitutions, no albumin handle, short-acting. Often confused with CJC-1295; the Q&A above distinguishes them.
For researchers placing orders: because the DAC and no-DAC versions are different materials with different literature attached, precision in naming matters. The published human data describes the DAC version. Research materials should come only from suppliers explicit about research-use-only status and precise about which compound they supply. Our Semax 10mg and Selank 10mg research listings follow the same explicit research-use framing.
What Is CJC-1295 in Regulatory Terms
A complete answer to what is CJC-1295 includes its regulatory status, because confusion here is common. CJC-1295 is not an approved medicine in any jurisdiction the published literature describes; its clinical trials were investigational studies, and the development program did not result in a marketed product. In the research-supply context, it exists as a research compound — handled, labeled, and sold for laboratory investigation only. That status is not a technicality: it determines what claims can legally and honestly be made about the compound, and it is why this explainer describes findings rather than effects.
Researchers sometimes ask whether CJC-1295 appears on any regulatory peptide lists or compounding nominations. The honest answer is that such lists are jurisdiction-specific and change over time; the FDA’s drug information pages are the authoritative reference for US status. What does not change is the baseline: a compound without approval is a research compound, and the what is CJC-1295 answer stays in the research lane regardless of where else the name appears.
Q: If the trials showed real effects, why is CJC-1295 not a medicine?
A: Because showing a physiological effect in healthy volunteers is not the same as demonstrating safety and efficacy for a therapeutic indication — and the latter is what approval requires. The published CJC-1295 trials measured hormone-axis activity, not treatment outcomes. Drug development is full of compounds with interesting pharmacology that never became medicines; interesting is a research property, not a regulatory one.
What Is CJC-1295: Key Takeaways
- What is CJC-1295? A synthetic 29-amino-acid GHRH analogue with four stabilizing substitutions and a DAC albumin-binding modification that extends its activity window to days.
- It acts at the top of the growth hormone axis, mimicking the hypothalamic GHRH signal; published trials report amplified pulsatile GH release and elevated IGF-1 in healthy volunteers.
- CJC-1295 with DAC and Mod GRF(1-29) without DAC are different research materials — the human trial literature attaches to the DAC version.
- It is a research compound, not an approved medicine; its development program did not produce a therapeutic product.
- Nothing in this explainer is usage guidance. The compound exists in the literature as a studied research tool.
That layered structure is also what makes what is CJC-1295 a question worth answering carefully rather than with a one-line label. Calling it “a GHRH peptide” is true but incomplete — it omits the substitutions that protect it, the DAC that extends it, and the regulatory reality that defines how it can be discussed. The full answer to what is CJC-1295 is therefore three sentences, not one: a stabilized GHRH(1-29) analogue, extended by albumin-binding chemistry, studied in human trials and now a research-compound reference. Researchers who carry all three layers into the literature will read it correctly; those who carry only one will not.
What Is CJC-1295: Final Research Notes
The complete answer to what is CJC-1295 is a compact one: a natural hormone signal, re-engineered for durability, studied in human trials, and now a fixture of the research-compound landscape. Its structure tells you what it is; its timeline tells you what became of it; and the distinction between the DAC and no-DAC versions tells you how to read any source that mentions it. Kept in that frame — structure, axis, history, variants — the compound is straightforward to understand and hard to misread.
Researchers who want the measured outcomes behind this explainer should read the companion CJC-1295 benefits roundup; those comparing research-peptide formats more broadly can see our Selank vs Semax research comparison and our Semax and Selank nasal spray research overviews. Primary trials are indexed on PubMed, and the FDA’s drug information pages provide the regulatory context for research compounds generally.
What Is CJC-1295: Frequently Asked Questions
The questions researchers ask most about what CJC-1295 is — answered in research framing.
What is CJC-1295 in simple terms?
CJC-1295 is a synthetic analogue of growth hormone–releasing hormone (GHRH): a 29-amino-acid peptide with stabilizing substitutions and a DAC modification that binds albumin and extends its activity window to days. It is a research compound used to study sustained GHRH-receptor activation — not a medicine.
What is the difference between CJC-1295 with DAC and without DAC?
The DAC (Drug Affinity Complex) version binds serum albumin and stays active for days; the version without DAC (often called Mod GRF 1-29) lacks the albumin handle and acts for a much shorter window. They are different research materials, and the published human trial data describes the DAC version.
How does CJC-1295 work in research terms?
It mimics GHRH at the pituitary GHRH receptor, signaling growth hormone release. Published trials report that it amplifies the body’s own pulsatile GH secretion and raises IGF-1 levels in healthy volunteers. These are research findings, not therapeutic claims — see our CJC-1295 benefits roundup for the measured outcomes.
Is CJC-1295 FDA-approved?
No. CJC-1295 is not an FDA-approved drug. Its development program did not produce an approved medicine, and it is handled as a research compound for laboratory and scientific investigation. The FDA’s drug information pages explain the regulatory framework.
Is CJC-1295 the same as sermorelin or ipamorelin?
No. Sermorelin is another GHRH(1-29) analogue without the DAC modification (short-acting). Ipamorelin is a ghrelin-receptor agonist — a different receptor on the same pituitary cells. Same downstream hormone, different research tracks.
Where can researchers read the primary research?
The clinical trials are indexed on PubMed. Background on the hormone axis is at Wikipedia’s GHRH article. Research materials should come only from suppliers explicit about research-use-only status.
